Acrux Limited (ACR.AX)

0.0580 0.0000 (0.00%) At close: 01:43PM AEST

Acrux Limited

103-113, Stanley Street
West Melbourne, VIC 3003
Australia
61 3 8379 0100
https://www.acrux.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus	CEO, MD & Executive Director	583.57k	N/A	1966
Ms. Joanna Johnson B.E., BEc, ICAA	CFO & Company Secretary	287.17k	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Corporate governance

Acrux Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.